Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Longeveron Inc's Business Segments
Longeveron Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment Aggregation Before Other Operating Segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment Aggregation Before Other Operating Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $ 0 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Clinical trial revenue95%
- Contract manufacturing revenue5%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Clinical trial revenue | $ 0 | 95% |
| Contract manufacturing revenue | $ 0 | 5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Longeveron Inc
Longeveron Inc. is a leading regenerative medicine company that is dedicated to developing innovative cellular therapies to improve the health and quality of life for patients suffering from chronic diseases. The company focuses on developing therapies using mesenchymal stem cells (MSCs), which have the potential to restore damaged tissues and promote healing in the body.
Longeveron’s research and development efforts are centered around investigating the therapeutic potential of MSCs derived from adult donors. These stem cells have the ability to differentiate into various cell types and have immunomodulatory properties, making them an ideal candidate for treating a wide range of conditions.
One of the key areas of focus for Longeveron is aging-related diseases and conditions. The company aims to develop therapies that can help address age-related issues such as frailty, Alzheimer's disease, and aging-associated cardiovascular diseases. By utilizing the regenerative properties of MSCs, Longeveron aims to improve the overall health and well-being of aging populations.
Longeveron’s flagship product, Lomecel-B, is a proprietary MSC therapy that has shown promising results in clinical trials. Lomecel-B is derived from the bone marrow of healthy adult donors and has been shown to have immunoregulatory effects and enhance tissue repair and regeneration. The therapy is administered through intravenous infusion and has demonstrated safety and efficacy in early clinical trials.
The company is actively involved in rigorous clinical research programs to further evaluate and expand the applications of Lomecel-B. Longeveron’s clinical trials are designed to assess the safety, tolerability, and efficacy of their cellular therapies in a variety of indications, such as aging frailty, Alzheimer's disease, muscular dystrophy, and traumatic brain injury.
Longeveron is also committed to maintaining high-quality standards in their research and development processes. The company follows strict Good Manufacturing Practices (GMP) and works closely with regulatory authorities to ensure compliance with applicable guidelines and regulations. Longeveron collaborates with leading academic institutions, hospitals, and research centers to conduct clinical studies and advance the development of their cellular therapies.
In addition to its research and development activities, Longeveron is actively engaged in educational initiatives and public outreach programs. The company aims to raise awareness about the potential of regenerative medicine and promote a better understanding of the role of stem cells in health and disease.
Overall, Longeveron Inc. is a pioneering regenerative medicine company that is dedicated to developing innovative cellular therapies to address the unmet medical needs of patients suffering from chronic diseases. Through their research, clinical trials, and commitment to quality, Longeveron is at the forefront of the field, striving to improve the lives of individuals around the world.
Longeveron’s research and development efforts are centered around investigating the therapeutic potential of MSCs derived from adult donors. These stem cells have the ability to differentiate into various cell types and have immunomodulatory properties, making them an ideal candidate for treating a wide range of conditions.
One of the key areas of focus for Longeveron is aging-related diseases and conditions. The company aims to develop therapies that can help address age-related issues such as frailty, Alzheimer's disease, and aging-associated cardiovascular diseases. By utilizing the regenerative properties of MSCs, Longeveron aims to improve the overall health and well-being of aging populations.
Longeveron’s flagship product, Lomecel-B, is a proprietary MSC therapy that has shown promising results in clinical trials. Lomecel-B is derived from the bone marrow of healthy adult donors and has been shown to have immunoregulatory effects and enhance tissue repair and regeneration. The therapy is administered through intravenous infusion and has demonstrated safety and efficacy in early clinical trials.
The company is actively involved in rigorous clinical research programs to further evaluate and expand the applications of Lomecel-B. Longeveron’s clinical trials are designed to assess the safety, tolerability, and efficacy of their cellular therapies in a variety of indications, such as aging frailty, Alzheimer's disease, muscular dystrophy, and traumatic brain injury.
Longeveron is also committed to maintaining high-quality standards in their research and development processes. The company follows strict Good Manufacturing Practices (GMP) and works closely with regulatory authorities to ensure compliance with applicable guidelines and regulations. Longeveron collaborates with leading academic institutions, hospitals, and research centers to conduct clinical studies and advance the development of their cellular therapies.
In addition to its research and development activities, Longeveron is actively engaged in educational initiatives and public outreach programs. The company aims to raise awareness about the potential of regenerative medicine and promote a better understanding of the role of stem cells in health and disease.
Overall, Longeveron Inc. is a pioneering regenerative medicine company that is dedicated to developing innovative cellular therapies to address the unmet medical needs of patients suffering from chronic diseases. Through their research, clinical trials, and commitment to quality, Longeveron is at the forefront of the field, striving to improve the lives of individuals around the world.
Longeveron Inc. is a biotechnology company that focuses primarily on developing cell-based therapies aimed at treating age-related and cardiac conditions. The company is at the forefront of research in regenerative medicine, leveraging its proprietary technology platforms related to mesenchymal stem cells. Here is an extensive description of the segments, products, and services offered by Longeveron Inc.
Segments
Longeveron operates primarily in the following segments:
1. Regenerative Medicine: This is the core focus of the company, utilizing stem cell therapies to address various medical conditions, particularly those associated with aging and heart disease.
2. Clinical Trials: Longeveron is involved in conducting clinical trials to test the efficacy and safety of its therapies, often collaborating with academic institutions and medical facilities.
3. Product Development: The company is dedicated to the research and development of innovative therapies that can improve outcomes for patients with chronic diseases and age-related ailments.
4. Commercialization: Longeveron is also focused on bringing its products to market, which entails navigating regulatory processes and working towards approval from various health authorities.
Products
Longeveron has several innovative products in its pipeline, each targeting specific medical conditions:
1. Lomecel-B:
- Description: Lomecel-B is an investigational drug composed of proprietary allogeneic (donor-derived) mesenchymal stem cells (MSCs) that have been shown to have immunomodulatory and regenerative properties.
- Indications: Primarily focused on treating patients with hypoplastic left heart syndrome (HLHS) in infants and age-related conditions such as frailty, heart failure, and Alzheimers disease.
- Mechanism of Action: It works through a variety of mechanisms, including modulation of inflammation, stimulation of tissue repair, and enhancement of cardiovascular function.
2. Longeveron’s Clinical Trials:
- Longeveron conducts clinical trials for various products, actively researching the use of Lomecel-B and other stem cell therapies for conditions like aging and heart-related disorders. This segment emphasizes the transition from experimental phases to potentially marketable therapies.
Services
In addition to its products, Longeveron offers various services that complement its offerings in regenerative medicine:
1. Clinical Research Services:
- Conducting Clinical Trials: Longeveron runs clinical trials to assess the safety and efficacy of its cell therapies. They often collaborate with hospitals and research institutions, providing oversight and expertise in stem cell application.
2. Regulatory Support:
- Longeveron assists in navigating the complex regulatory landscape associated with bringing new biotechnology products to market. This includes preparing necessary documentation for trials and working with regulatory bodies to ensure compliance with health regulations.
3. Consultative Services:
- The company may provide consultation on the use of stem cell technology in clinical practices, offering insights into best practices, safety protocols, and application methods for healthcare providers interested in regenerative therapies.
4. Education and Training Programs:
- Longeveron may engage in educational initiatives to inform healthcare professionals and the general public about the benefits and science behind stem cell therapies.
5. Partnerships with Healthcare Institutions:
- By collaborating with hospitals and academic research centers, Longeveron strengthens its clinical trial capabilities and expands its reach in the regenerative medicine landscape.
Research and Development
Investments in research and development are crucial for Longeveron’s growth, focused on both improving existing products and discovering new therapeutic applications for stem cell technology. This R&D is often backed by scientific collaboration with leading researchers and institutions in the field of regenerative medicine.
Conclusion
In summary, Longeveron Inc. plays a significant role in the biopharmaceutical landscape, primarily through the development of innovative stem cell therapies aimed at age-related and cardiac conditions. With a strong focus on research, clinical trials, and effective commercialization strategies, Longeveron continues to advance the field of regenerative medicine, contributing to the potential improvement of patient outcomes in chronic and age-related diseases.
Segments
Longeveron operates primarily in the following segments:
1. Regenerative Medicine: This is the core focus of the company, utilizing stem cell therapies to address various medical conditions, particularly those associated with aging and heart disease.
2. Clinical Trials: Longeveron is involved in conducting clinical trials to test the efficacy and safety of its therapies, often collaborating with academic institutions and medical facilities.
3. Product Development: The company is dedicated to the research and development of innovative therapies that can improve outcomes for patients with chronic diseases and age-related ailments.
4. Commercialization: Longeveron is also focused on bringing its products to market, which entails navigating regulatory processes and working towards approval from various health authorities.
Products
Longeveron has several innovative products in its pipeline, each targeting specific medical conditions:
1. Lomecel-B:
- Description: Lomecel-B is an investigational drug composed of proprietary allogeneic (donor-derived) mesenchymal stem cells (MSCs) that have been shown to have immunomodulatory and regenerative properties.
- Indications: Primarily focused on treating patients with hypoplastic left heart syndrome (HLHS) in infants and age-related conditions such as frailty, heart failure, and Alzheimers disease.
- Mechanism of Action: It works through a variety of mechanisms, including modulation of inflammation, stimulation of tissue repair, and enhancement of cardiovascular function.
2. Longeveron’s Clinical Trials:
- Longeveron conducts clinical trials for various products, actively researching the use of Lomecel-B and other stem cell therapies for conditions like aging and heart-related disorders. This segment emphasizes the transition from experimental phases to potentially marketable therapies.
Services
In addition to its products, Longeveron offers various services that complement its offerings in regenerative medicine:
1. Clinical Research Services:
- Conducting Clinical Trials: Longeveron runs clinical trials to assess the safety and efficacy of its cell therapies. They often collaborate with hospitals and research institutions, providing oversight and expertise in stem cell application.
2. Regulatory Support:
- Longeveron assists in navigating the complex regulatory landscape associated with bringing new biotechnology products to market. This includes preparing necessary documentation for trials and working with regulatory bodies to ensure compliance with health regulations.
3. Consultative Services:
- The company may provide consultation on the use of stem cell technology in clinical practices, offering insights into best practices, safety protocols, and application methods for healthcare providers interested in regenerative therapies.
4. Education and Training Programs:
- Longeveron may engage in educational initiatives to inform healthcare professionals and the general public about the benefits and science behind stem cell therapies.
5. Partnerships with Healthcare Institutions:
- By collaborating with hospitals and academic research centers, Longeveron strengthens its clinical trial capabilities and expands its reach in the regenerative medicine landscape.
Research and Development
Investments in research and development are crucial for Longeveron’s growth, focused on both improving existing products and discovering new therapeutic applications for stem cell technology. This R&D is often backed by scientific collaboration with leading researchers and institutions in the field of regenerative medicine.
Conclusion
In summary, Longeveron Inc. plays a significant role in the biopharmaceutical landscape, primarily through the development of innovative stem cell therapies aimed at age-related and cardiac conditions. With a strong focus on research, clinical trials, and effective commercialization strategies, Longeveron continues to advance the field of regenerative medicine, contributing to the potential improvement of patient outcomes in chronic and age-related diseases.